A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.

Hortobagyi, Gabriel N; Heim, William; Hutchins, Laura; Rivera, Edgardo; Mason, Bernard; Booser, Daniel J; Kirshner, Jeffrey

Hortobagyi, Gabriel N; Heim, William; Hutchins, Laura; Rivera, Edgardo; Mason, Bernard; Booser, Daniel J; Kirshner, Jeffrey.

Affiliation

Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030-4009, USA. ghortoba@mdanderson.org

Cancer ; 116(6): 1440-5, 2010 Mar 15.

Article in En | MEDLINE | ID: mdl-20091835

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Breast Neoplasms/pathology; Drug Administration Schedule; Female; Humans; Leucovorin/administration & dosage; Middle Aged; Neoplasm Metastasis; Recurrence; Retreatment; Tegafur/administration & dosage; Uracil/administration & dosage

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Cancer Year: 2010 Document type: Article

Fulltext

XML

PubMed Links

Search on Google